Based on these data, clinical trials of RAF/MEK and RAF/EGFR inhibitor combinations were initiated in patients with BRAF-mutant CRC, yielding increased response rates of 12%, and 13–26% respectively.8,9. This evidence concerns the gene MAP2K7 and colorectal carcinoma.